Expansion Global Distribution Agreement with GE
Imaging Biometrics Limited has expanded its global distribution agreement with GE HealthCare to include FTB Express maps and QSMetric, enhancing access to advanced neuroimaging solutions. This amendment builds upon the existing distribution of IB Neuro and Delta T1 maps, which are crucial for brain tumor diagnosis and treatment monitoring. FTB Express offers accelerated processing for Fractional Tumor Burden maps, providing rapid insights into tumor versus non-tumor tissue and treatment effects. QSMetric, a patented quantitative susceptibility mapping software, supports a wider range of clinical applications including neurodegenerative disease assessment and neurosurgery targeting.
Select text to share a quote on X · sign in to keep highlights & notes in your IBAI notes
Imaging Biometrics Expands Global Distribution Agreement with GE HealthCare to Include FTB Express Maps and QSMetric™
Imaging Biometrics (IB), a leader in advanced neuroimaging solutions, announces an amendment to its distribution agreement with GE HealthCare, expanding access to two innovative offerings: FTB Express maps and QSMetric.
The agreement already includes IB Neuro and Delta T1 maps, widely adopted together to assist clinicians in diagnosing, planning, and monitoring treatment response for brain tumor patients. Delta T1 maps provide rapid, objective delineation of contrast-enhancing regions, while IB Neuro generates standardized (quantitative) MR DSC perfusion images of relative cerebral blood volume (sRCBV), which eliminates manual tissue normalization. These outputs serve as inputs for Fractional Tumor Burden (FTB) maps, which deliver automated visualization of tumor versus non-tumor tissue and treatment effects within enhancing regions. FTB Express accelerates this process, enabling clinicians to quickly access actionable insights for patient care.
QSMetric is a patented quantitative susceptibility mapping software that processes gradient echo brain images to visualize tissue structures and measure susceptibility values. This capability supports a broad range of clinical applications, including targeting for deep brain stimulation (DBS) surgery, neurodegenerative disease assessment, multiple sclerosis, and more.
Katie Anderson, Global MR Visualization Product Manager at GE HealthCare, said, "We are excited to expand our collaboration with Imaging Biometrics to enable access for our customers to these clinically important capabilities."
The Directors of the Company accept responsibility for the contents of this announcement.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.